Trials / Completed
CompletedNCT01625559
Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)
A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- CHABiotech CO., Ltd · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD
Detailed description
* to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD * to evaluate the preliminary efficacy of MA09-hPRE in patients with SMD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MA09-hRPE | MA09-hRPE cells |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2012-06-21
- Last updated
- 2024-04-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01625559. Inclusion in this directory is not an endorsement.